Topics:

RAS Mutations Enhance Chemotherapy in AML

RAS Mutations Enhance Chemotherapy in AML

Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission. Their relapse rate was 45%, compared with 68% for high-dose patients with normal RAS, according to a CALGB study published online (JCO June 16, 2008). This could allow doctors to identify patients who would benefit from aggressive therapy.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.